Literature DB >> 9609273

The Ipswich Childbirth Study: 2. A randomised comparison of polyglactin 910 with chromic catgut for postpartum perineal repair.

C Mackrodt1, B Gordon, E Fern, S Ayers, A Truesdale, A Grant.   

Abstract

OBJECTIVE: To compare polyglactin 910 sutures with chromic catgut sutures for postpartum perineal repair.
DESIGN: A stratified randomised controlled trial, using a 2 x 2 factorial design.
SETTING: The maternity unit at Ipswich Hospital NHS Trust, a district general hospital, between 1992 and 1994. SAMPLE: 1780 women who had sustained an episiotomy or first or second degree tear following a spontaneous or simple instrumental delivery.
METHODS: Policies of repair with polyglactin 910 or chromic catgut were compared. Both groups were assessed by a research midwife completing questionnaires at 24 to 48 hours and at ten days postpartum, and by self-completed questionnaires at three months after birth. MAIN OUTCOME MEASURES: 1. 24 to 48 hours postpartum: perineal pain, healing; 2. ten days postpartum: perineal pain, healing and removal of sutures; 3. three months postpartum: perineal pain, removal of sutures, resuturing, dyspareunia, and failure to resume pain-free intercourse.
RESULTS: Completed questionnaires were returned for 99% of women at both 24 to 48 hours and ten days and by 93% of women three months postpartum. The two groups were similar at trial entry. Significantly fewer women allocated to the polyglactin 910 reported pain in the previous 24 hours at both 24 to 48 hours (59% vs 67%; RR 0.89, 95% CI 0.83-0.95; 2P < 0.01), and ten days (24% vs 29%; RR 0.81, 95% CI 0.69-0.95; 2P = 0.01). At three months postpartum there was no clear difference between the groups in terms of perineal pain, dyspareunia or failure to resume pain-free intercourse. More women in the polyglactin 910 group reported that some suture material had been removed (12% vs 7%; RR 1.62, 95% CI 1.19-2.21; 2P < 0.01). Three women in the polyglactin 910 group had required resuturing compared with ten in the chromic catgut group (RR 0.30; 95% CI 0.08-1.09; 2P = 0.1).
CONCLUSIONS: Using polyglactin 910 rather than chromic catgut for perineal repair leads to about one fewer women among every 20 having perineal pain and using analgesia ten days postpartum. Its only apparent disadvantage is that more women, again estimated as 1 in 20, report having material removed during healing. Data from this and other trials suggest that for every 100 women repaired with a polyglycolic acid-based material, about one fewer will require resuturing.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9609273     DOI: 10.1111/j.1471-0528.1998.tb10131.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  8 in total

Review 1.  Absorbable suture materials for primary repair of episiotomy and second degree tears.

Authors:  Christine Kettle; Therese Dowswell; Khaled Mk Ismail
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

Review 2.  Perineal care.

Authors:  Julie Frohlich; Christine Kettle
Journal:  BMJ Clin Evid       Date:  2015-03-10

3.  Postpartum perineal pain in a low episiotomy setting: association with severity of genital trauma, labor care, and birth variables.

Authors:  Lawrence Leeman; Anne M Fullilove; Noelle Borders; Regina Manocchio; Leah L Albers; Rebecca G Rogers
Journal:  Birth       Date:  2009-12       Impact factor: 3.689

4.  A prospective randomized comparative study of vicryl rapide versus chromic catgut for episiotomy repair.

Authors:  A Bharathi; D B Dharma Reddy; G S Sharath Kote
Journal:  J Clin Diagn Res       Date:  2012-12-24

Review 5.  Perineal care.

Authors:  Chris Kettle; Susan Tohill
Journal:  BMJ Clin Evid       Date:  2011-04-11

Review 6.  Absorbable synthetic versus catgut suture material for perineal repair.

Authors:  C Kettle; R B Johanson
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 7.  Perineal care.

Authors:  Chris Kettle; Susan Tohill
Journal:  BMJ Clin Evid       Date:  2008-09-24

8.  Features of randomised trials designed by the NPEU Perinatal Trials Service during Adrian Grant's directorship.

Authors:  Diana Elbourne
Journal:  Reprod Health       Date:  2018-07-09       Impact factor: 3.223

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.